DDInter1055 DDInter1577
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Levofloxacin {u} (Compound) upregulates {v} (Gene) SELL
SELL {u} (Gene) is upregulated by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Levofloxacin {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Levofloxacin {u} (Compound) upregulates {v} (Gene) SELL
SELL {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Levofloxacin {u} (Compound) causes {v} (Side Effect) Laryngitis
Laryngitis {u} (Side Effect) is caused by {v} (Compound) Salmeterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Relugolix
Levofloxacin {u} (Compound) causes {v} (Side Effect) Laryngitis
Laryngitis {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Levofloxacin {u} (Compound) resembles {v} (Compound) Ofloxacin
Ofloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Levofloxacin {u} (Compound) resembles {v} (Compound) Ofloxacin
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Levofloxacin (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Levofloxacin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Levofloxacin (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Levofloxacin (Compound) causes Laryngitis (Side Effect) and Laryngitis (Side Effect) is caused by Salmeterol (Compound) and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Levofloxacin (Compound) causes Laryngitis (Side Effect) and Laryngitis (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Relugolix
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound) and Ticagrelor may lead to a major life threatening interaction when taken with Relugolix
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Relugolix